Skip to content

Message Board

The Sarcoma Coalition is committed to support sarcoma research through: Sarcoma member organizations posting research projects that encompass a variety of sarcoma subtypes where collaboration on the Sarcoma Coalition website Message Board to announce:
– Collaborative opportunities to promote sarcoma research initiatives
– Explore co-funding opportunities that may arise through the research community
– Post successful research collaborations on FB and provide alerts for the Sarcoma Coalition newsletters,
with follow-up research collaboration results also posted on the Message Board of the Sarcoma Coalition website.

PDF and QR Code for sharing info about the Sarcoma Coalition:

Meeting dates for 2024: July 18, October 17

New Messages


SARCOMA CLINICAL TRIAL FUNDED BY STAND UP TO CANCER REDUCES RISK OF RELAPSE BY 43% – David Kirsch MD PhD, unveiled the SU2C-SARC032 findings at ASCO 2024. SARC032 is a global, multicenter, randomized phase 2 study evaluating the safety and effectiveness of combining pembrolizumab (pembro) with standard radiation therapy (RT) and surgery for patients with stage III undifferentiated pleomorphic sarcoma (UPS) and pleomorphic/dedifferentiated liposarcoma (LPS). The results indicate that adding pembro decreases the risk of cancer recurrence by 43% two years after treatment. This remarkable achievement is the result of a collaborative effort, with SARC, as the trial sponsor, proudly working together with Dr. Kirsch, Stand Up To Cancer, Merck, and other partners on this significant clinical research.

SARC Press release on new link to sarcoma centers registry published 5/8/204. New link on this page.

Chondrosarcoma Foundation Introduces a new Patient Guide: Making the Decision to enroll in a Clinical Trial – The new guide on “Making the Decision to Enroll in a Clinical Trial” is posted on our web site under the Helpful Information Menu. It is one of four guides the foundation has created to provide straightforward information to help patients and their families. When given the opportunity to enroll in a trial, CS Warriors who read the content in the guide will know enough to ask pertinent questions to the trial staff to help make decisions about their care. We encourage everyone to check out this and the other three guides to gain more knowledge about chondrosarcoma and your journey. We would also be happy to send you digital copies of the publications by sending a request to

Cancer Precision Medicine Commons ( is presenting a webinar for patient advocacy groups and medical professionals on, “Best Practice Recommendations for development of patient education resources about Biomarker Testing and Genetic Testing for Inherited Cancer Risk” on May 22 at 2PM ET. Commons members will review resources and provide action and suggestions for utilizing them to support your efforts to educate patients about these important precision medicine tools. Register here:

Dr. Anush Kalbasi, Stanford Research Radiation Therapist will meet with patients to discuss:
three topics, one involving a recent research publication. – a recorded session for May 8th – 2:30 pm MT Registration link to come.


Rare Disease Congressional Caucus – Please contact your Members of Congress and urge them to join the Rare Disease Congressional Caucus.


Sarcoma Cancer Foundation of Canada – RESEARCH INTO RARE FORM OF VASCULAR SARCOMA CANCER RECEIVES $1 MILLION IN FUNDING – July 5, 2022 –Sarcoma Cancer Foundation of Canada Celebrates Largest Ever Investment in Canadian EHE Sarcoma Cancer Research. TORONTO, ON, July 5, 2022 – The Sarcoma Cancer Foundation of Canada is pleased to announce a one-million-dollar investment into an exciting new research initiative that will evolve the collective baseline of Epithelioid Hemangioendothelioma (EHE), a rare vascular form of a sarcoma. This Canadian-led research brings together an international team of experts and has the potential to create positive impacts for the EHE community in Canada, and around the world. Read more here.

Rhabdo Data Analysis – A recently formed Rhabdomyosarcoma coalition of four foundations, Summer’s Way, Friends of TJ, Sebastian Strong and Maddie’s Promise have joined forces to advance Rhabdo data analysis. These foundations are jointly supporting the work of the Children’s Oncology Group Soft Tissue Sarcoma Committee through funding of a Master Statistician. This statistician is currently working on four research projects related to rhabdomyosarcoma including (1) rhabdomyosarcoma of the head and neck, (2) rhabdomyosarcoma of the orbit, (3) identification of biomarkers in relapsed rhabdomyosarcoma patients and (4) impact of race and ethnicity in rhabdomyosarcoma outcomes. Over 2,000 specimens will be entered into a database for analysis, with a potential to provide a targeted approach towards treatment and improve the outcomes of children with rhabdomyosarcoma.